Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

Publikation

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

Wissenschaftlicher Artikel/Review - 23.05.2010

Rao S, Beadman C, Kurek R, Archer C, Wilke H, Valladares-Ayerbes M, Ruhstaller Thomas, Gilligan D, Sumpter K, Cunningham D, Starling N, Oates J

Zitation

Rao S, Beadman C, Kurek R, Archer C, Wilke H, Valladares-Ayerbes M, Ruhstaller T, Gilligan D, Sumpter K, Cunningham D, Starling N, Oates J. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010; 21:2213-9.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Ann Oncol 2010; 21

Veröffentlichungsdatum

23.05.2010

eISSN (Online)

1569-8041

Seiten

2213-9

Kurzbeschreibung/Zielsetzung

Clinical data showed promising antitumour activity with feasible tolerability for matuzumab plus epirubicin, cisplatin and capecitabine (ECX) chemotherapy in untreated advanced oesophago-gastric (OG) cancer. The aim was to evaluate the efficacy of matuzumab plus ECX versus ECX alone.